Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

MLA

Moodie, Zoe, et al. “Safety and Immunogenicity of a Subtype C ALVAC-HIV (VCP2438) Vaccine Prime plus Bivalent Subtype C Gp120 Vaccine Boost Adjuvanted with MF59 or Alum in Healthy Adults without HIV (HVTN 107): A Phase 1/2a Randomized Trial.” PLoS Medicine, vol. 21, no. 3, Mar. 2024, p. e1004360. EBSCOhost, https://doi.org/10.1371/journal.pmed.1004360.

APA

Moodie, Z., Andersen-Nissen, E., Grunenberg, N., Dintwe, O. B., Omar, F. L., Kee, J. J., Bekker, L.-G., Laher, F., Naicker, N., Jani, I., Mgodi, N. M., Hunidzarira, P., Sebe, M., Miner, M. D., Polakowski, L., Ramirez, S., Nebergall, M., Takuva, S., Sikhosana, L., … Goepfert, P. (2024). Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Medicine, 21(3), e1004360. https://doi.org/10.1371/journal.pmed.1004360

Chicago

Moodie, Zoe, Erica Andersen-Nissen, Nicole Grunenberg, One B. Dintwe, Faatima Laher Omar, Jia J. Kee, Linda-Gail Bekker, et al. 2024. “Safety and Immunogenicity of a Subtype C ALVAC-HIV (VCP2438) Vaccine Prime plus Bivalent Subtype C Gp120 Vaccine Boost Adjuvanted with MF59 or Alum in Healthy Adults without HIV (HVTN 107): A Phase 1/2a Randomized Trial.” PLoS Medicine 21 (3): e1004360. doi:10.1371/journal.pmed.1004360.